410 related articles for article (PubMed ID: 32425120)
1. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
Roman YM; Hernandez AV; White CM
Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
[TBL] [Abstract][Full Text] [Related]
2. The Emerging Role of Inflammation in Cardiovascular Disease.
Martinez BK; White CM
Ann Pharmacother; 2018 Aug; 52(8):801-809. PubMed ID: 29557210
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
[TBL] [Abstract][Full Text] [Related]
4. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
Ajala ON; Everett BM
Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
[TBL] [Abstract][Full Text] [Related]
6. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
7. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?].
Hoogeveen RM; Stroes ESG; Cornel JH
Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620
[TBL] [Abstract][Full Text] [Related]
8. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.
Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH
Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
[TBL] [Abstract][Full Text] [Related]
10. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
[TBL] [Abstract][Full Text] [Related]
11. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial.
Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R
BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621
[TBL] [Abstract][Full Text] [Related]
12. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibition and inflammation: A narrative review.
Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR
Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822
[TBL] [Abstract][Full Text] [Related]
14. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
Nidorf SM; Thompson PL
Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
[TBL] [Abstract][Full Text] [Related]
15. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
[TBL] [Abstract][Full Text] [Related]
16. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
[TBL] [Abstract][Full Text] [Related]
17. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
Ridker PM
Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
[TBL] [Abstract][Full Text] [Related]
18. Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial.
Gholoobi A; Askari VR; Naghedinia H; Ahmadi M; Vakili V; Baradaran Rahimi V
Inflammopharmacology; 2021 Oct; 29(5):1379-1387. PubMed ID: 34420187
[TBL] [Abstract][Full Text] [Related]
19. Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?
Whayne TF
Am J Cardiovasc Drugs; 2021 Jan; 21(1):1-10. PubMed ID: 32356107
[TBL] [Abstract][Full Text] [Related]
20. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis.
Hafiane A; Daskalopoulou SS
Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
